دورية أكاديمية
Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment
| العنوان: | Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment |
|---|---|
| المؤلفون: | Bashar Aqel, Michael Leise, Hugo E. Vargas, Kymberly D. Watt, Andrew P. Keaveny, Nan Zhang, Surakit Pungpapong |
| المصدر: | Annals of Hepatology, Vol 17, Iss 5, Pp 815-821 (2018) |
| بيانات النشر: | Elsevier, 2018. |
| سنة النشر: | 2018 |
| المجموعة: | LCC:Specialties of internal medicine |
| مصطلحات موضوعية: | Hepatitis C, Direct acting antiviral agents (DAA), Simeprevir, Sofosbuvir, Ledipasvir, Relapser, Specialties of internal medicine, RC581-951 |
| الوصف: | Introduction and aim. Approximately 10%-15% of patients with hepatitis C genotype 1 (HCV GT1) experience virological relapse after all-oral antiviral regimen using simeprevir (SMV) and sofosbuvir (SOF). The efficacy and safety of treating such relapsers using ledipasvir/sofosbuvir (LDV/SOF) with/without ribavirin (RBV) has been limited.Objective. Report the virological response and safety of LDV/SOF with/without RBV for 12-24 weeks in treating HCV GT1 relapsers after SMV + SOF.Material and methods. Patients treated with standardized clinical protocol utilizing LDV/SOF with/without RBV at three transplant centers were retrospectively reviewed.Results. Forty-five patients (29% post-LT, 82% male, 13% non-white, 73% subtype 1a, 86% IL28B CT/ TT, 78% F3-4) started LDV/SOF with/without RBV at a median of 22 weeks (range 7-55 weeks) after the last dose of SMV+SOF treatment. Thirty-seven patients received LDV/SOF for 24 weeks (24/37 patients with RBV) and eight patients received LDV/SOF for 12 weeks (5/8 patients with RBV). RBV dose was adjusted for renal function. Sixteen patients who were RBV-ineligible received LDV/SOF without RBV for 12 or 24 weeks. SVR 12 was achieved in 96% (43/45) of patients. Baseline viral load, RBV use, or GT1 subtype did not impact SVR 12. Minimal adverse events were reported in those without RBV; 45% of patients who received RBV developed significant anemia requiring RBV dose reduction and/or discontinuation. In LT recipients, minimal immunosuppression dose adjustments were required and no biopsy-proven acute rejection occurred.Conclusions. Treatment with LDV/SOF with/without RBV for 12-24 weeks was very well tolerated and resulted in high SVR 12 rates (96%) in HCV GT1 relapsers to SMV + SOF treatment. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1665-2681 39547191 |
| Relation: | http://www.sciencedirect.com/science/article/pii/S1665268119302601; https://doaj.org/toc/1665-2681 |
| DOI: | 10.5604/01.3001.0012.3142 |
| URL الوصول: | https://doaj.org/article/3b8d6d4b01af49f395471913ce51f926 |
| رقم الأكسشن: | edsdoj.3b8d6d4b01af49f395471913ce51f926 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 16652681 39547191 |
|---|---|
| DOI: | 10.5604/01.3001.0012.3142 |